Journal
ONCOGENE
Volume 40, Issue 7, Pages 1205-1216Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-020-01598-0
Keywords
-
Funding
- Universita della Svizzera italiana
Ask authors/readers for more resources
Targeting the androgen receptor signaling axis has long been the main strategy for prostate cancer therapy, but stronger inhibition has led to a subset of cancers becoming AR-negative, with a poorer prognosis.
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative disease. Unfortunately, this process is intimately linked with a poor prognosis. Here, we review the molecular mechanisms that enable cancer cells to switch from an AR-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available